Truist has initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory updates for its drug candidate nomla for Friedreich’s ...

As previously reported, Truist initiated coverage of Larimar Therapeutics (LRMR) with a Buy rating and $18 price target Despite “promising” ...

Adam Sperling has been named the new executive director for the Truist Championship. His role starts Feb. 3 and he'll oversee ...

Money from the program will be used by nonprofit groups to help rebuild small businesses, housing and infrastructure in 39 ...

This was the stock's second consecutive day of gains.

Net interest margin, which measures lending profitability, expanded to 3.07%, compared with 2.95% a year earlier. Truist's ...

Geneos Wealth Management Inc. boosted its position in shares of Truist Financial Co. (NYSE:TFC – Free Report) by 3.2% in the ...

Leaders at the bank, which has been operating in DFW for more than a decade, want to capitalize on positive trends.

Truist Financial's Q4 beat EPS and revenue estimates, but noninterest expenses rose and specific lending segments faced ...

Truist raised the firm’s price target on Ally Financial (ALLY) to $47 from $42 and keeps a Buy rating on the shares after its Q4 earnings beat.

Influence Media Partners has confirmed that it has secured approximately $360 million in debt financing through an inaugural ...

Truist Financial Corp. continued to settle into its trimmer fee-income strategy during the fourth quarter by slightly ...